ACTRN12613000511730招募中不适用
ILLUMENATE Global: Prospective, single-arm, global multi-center study to evaluate the safety and performance of the CVI paclitaxel-coated percutaneous angioplasty balloon catheter in the treatment of de novo or restenotic lesions (excluding in-stent lesions) in the superficial and/or popliteal arteries to establish blood flow and to maintain vessel patency.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- Covidien
- 入组人数
- 370
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •General Inclusion Criteria 1. Has clinically significant symptomatic leg ischemia, requiring treatment of the SFA and/or popliteal artery. 2. Has a Rutherford Clinical Category of 2 - 4. Note: Rutherford Clinical Category 2-3 subjects should be entered into the study if conservative treatment and/or medicinal therapy have been unsuccessful. 3. Is at least 18 years old. 4. Has life expectancy > 1 year. 5. Is able and willing to provide written informed consent prior to study-specific procedures. 6. Is willing and capable of complying with the required follow-up visits, testing schedule and medication regimen. Angiographic Inclusion Criteria 1. Has evidence at the target lesion(s) of clinically and hemodynamically significant de novo stenosis or restenosis, or occlusion, in the SFA (1 cm distal to the ostium of the profunda) and/or popliteal artery, confirmed by angiography. 2. Has target limb with at least one patent (<50% stenosis) tibio-peroneal run-off vessel to the foot confirmed by baseline angiography or magnetic resonance angiography (MRA) or computed tomography angiography (CTA). Note: Treatment of outflow disease is NOT permitted. 3. Has 1 or 2 target lesion(s) with a cumulative length of no more than 20 cm. 4. Has target lesion(s) located >2 cm from any stent if the target vessel was previously stented. 5. Has a reference vessel diameter of 4 - 6 mm. 6. Has a successful exchangeable guidewire crossing of the lesion(s).
排除标准
- •General Exclusion Criteria 1. Is pregnant, of childbearing potential not taking adequate contraceptive measures, or nursing. 2. Has significant gastrointestinal bleeding or any coagulopathy that would contraindicate the use of anti-platelet therapy 3. Has known intolerance to study medications, paclitaxel or contrast agents that in the opinion of the investigator cannot be adequately pre-treated. 4. Is currently participating in another investigational device or drug study that would interfere with study endpoints. 5. Has history of hemorrhagic stroke within 3 months. 6. Has surgical or endovascular procedure of the target limb within 14 days prior to the index procedure. 7. Has any planned surgical intervention (requiring hospitalization) or endovascular procedure within 30 days after the index procedure. 8. Has had a previous peripheral bypass affecting the target limb. 9. Has unstable angina pectoris, myocardial infarction, liver failure, renal failure or chronic kidney disease within 30 days of the index procedure. Angiographic Exclusion Criteria 1. Has significant stenosis (greater than or equal to 50%) or occlusion of inflow tract that is not successfully revascularized (< 30% residual stenosis without death or major vascular complication) prior to treatment of the target lesion(s). Treatment of target lesion(s) is acceptable after successful treatment of inflow artery lesion(s). 2. Has an acute or sub-acute intraluminal thrombus within the target vessel. 3. Has in-stent restenosis or restenosis of the target lesion following previous treatment with a drug-coated balloon. 4. Has an aneurysmal target vessel. 5. Has perforation, dissection or other injury of the access or target vessel requiring stenting or surgical intervention prior to enrollment. 6. Has no normal arterial segment proximal to the target lesion in which duplex ultrasound velocity ratios can be measured. 7. Requires use of adjunctive therapies (i.e., laser, atherectomy, cryoplasty, scoring/cutting balloons, brachytherapy). 8. Has severe calcification that precludes adequate PTA treatment.
研究者
相似试验
进行中（未招募）
1 期
An International, Multicentre, Prospective, Single Arm Study to Assess the Effect on Voluntary Movements of AbobotulinumtoxinA 1500 U Administered in Both Upper and Lower Limbs in Conjunction with a Guided Self Rehabilitation Contract in Adult Subjects with Spastic HemiparesisEUCTR2016-001989-29-CZIpsen Pharma155
进行中（未招募）
1 期
An International, Multicentre, Prospective, Single Arm Study to Assess the Effect on Voluntary Movements of AbobotulinumtoxinA 1500 U Administered in Both Upper and Lower Limbs in Conjunction with a Guided Self Rehabilitation Contract in Adult Subjects with Spastic HemiparesisEUCTR2016-001989-29-FRIpsen Pharma SAS157
进行中（未招募）
1 期
A prospective, open-label, single arm, multinational, multi-centre, flexible dose, extension study of the SCoP 99824 with sertindole for patients suffering from schizophreniaPatients suffering from schizophrenia, according to the ICD-10, DSM-IV or regional classification criteriaMedDRA version: 9.1Level: LLTClassification code 10039626Term: SchizophreniaEUCTR2007-002160-10-FRH. Lundbeck A/S50
进行中（未招募）
不适用
A prospective, open-label, international, multicenter trial to investigate the efficacy and safety of NT 201, free of complexing proteins, in the treatment of glabellar frown lines - NT-SPUTNIKEUCTR2008-000549-73-DEMerz Pharmaceuticals GmbH101
撤回
不适用
A Prospective, Multicenter, Single Arm Real-World Registry Investigating the Clinical Use and Safety of the Lutonix® Drug Coated Balloon PTA Catheter for Treatment of Below-the-Knee (BTK) ArteriesNL-OMON42884utonix, Inc.30